| 1 |
34800002 | Pharmacokinetics of bempedoic acid in patients with renal impairment. | 2022 Mar |
1 |
| 2 |
34981622 | Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials. | 2022 May |
2 |
| 3 |
35143133 | [Bempedoïc acid, new cholesterol-lowering drug]. | 2022 Feb |
1 |
| 4 |
35619668 | Bempedoic acid: a novel oral LDL-cholesterol lowering agent. | 2022 |
2 |
| 5 |
33399194 | Bempedoic acid: Review of a novel therapy in lipid management. | 2021 Jan 5 |
2 |
| 6 |
33502687 | Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance. | 2021 Aug |
2 |
| 7 |
33818688 | Role of Bempedoic Acid in Clinical Practice. | 2021 Aug |
1 |
| 8 |
33847313 | [Bempedoic acid: mechanism of action]. | 2021 Apr |
4 |
| 9 |
34075028 | IGF1-mediated HOXA13 overexpression promotes colorectal cancer metastasis through upregulating ACLY and IGF1R. | 2021 Jun 1 |
1 |
| 10 |
34172394 | Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial. | 2021 Jul-Aug |
1 |
| 11 |
34435333 | Bempedoic Acid: A New Non-statin Drug for the Treatment of Dyslipidemia. | 2021 Oct |
1 |
| 12 |
34448822 | Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose-response model. | 2021 Aug 27 |
1 |
| 13 |
34635427 | The multifaceted therapeutic value of targeting ATP-citrate lyase in atherosclerosis. | 2021 Dec |
4 |
| 14 |
34839358 | ONECUT2 facilitates hepatocellular carcinoma metastasis by transcriptionally upregulating FGF2 and ACLY. | 2021 Nov 27 |
1 |
| 15 |
34909677 | ATP citrate lyase inhibitor Bempedoic Acid alleviate long term HFD induced NASH through improvement in glycemic control, reduction of hepatic triglycerides & total cholesterol, modulation of inflammatory & fibrotic genes and improvement in NAS score. | 2021 |
6 |
| 16 |
31499095 | ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review. | 2020 Jan |
4 |
| 17 |
32564642 | Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential. | 2020 Aug |
1 |
| 18 |
32763847 | Measurement of bempedoic acid and its keto metabolite in human plasma and urine using solid phase extraction and electrospray LC-MS/MS. | 2020 Oct 1 |
1 |
| 19 |
32980290 | Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. | 2020 Sep - Oct |
1 |
| 20 |
33025951 | Bempedoic acid: effect of ATP-citrate lyase inhibition on low-density lipoprotein cholesterol and other lipids. | 2020 Sep |
4 |
| 21 |
33276805 | Efficacy and safety of bempedoic acid alone or combining with other lipid-lowering therapies in hypercholesterolemic patients: a meta-analysis of randomized controlled trials. | 2020 Dec 4 |
1 |
| 22 |
29939848 | Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor: Review of a First-in-Class Medication with Potential Benefit in Statin-Refractory Cases. | 2019 Jan/Feb |
2 |
| 23 |
30586346 | Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis. | 2019 Feb |
3 |
| 24 |
30865796 | Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. | 2019 Mar 14 |
1 |
| 25 |
30922146 | Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. | 2019 Apr 2 |
1 |
| 26 |
31906686 | Current and future trends in the treatment of dyslipidemias. | 2019 Winter |
1 |
| 27 |
28059952 | ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia. | 2017 Apr |
2 |
| 28 |
27663902 | Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase. | 2016 Oct |
6 |
| 29 |
27892461 | Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. | 2016 Nov 28 |
5 |
| 30 |
26073398 | Adenosine triphosphate citrate lyase: Emerging target in the treatment of dyslipidemia. | 2015 May-Jun |
1 |